Chuang-Hsin Chiu1, Wen-Sheng Huang2,3, Chi-Wei Chang2,4,5, Ming-Hsien Lin6,7, Hung-Ming Wu8, Tsung-Hsun Yu9, Pao-Yeh Wang9, Yu-Yeh Kuo9, Ya-Yao Huang10,11, Chyng-Yann Shiue11,12, Skye Hsin-Hsien Yeh13. 1. Department of Nuclear Medicine, Tri-Service General Hospital, Taipei, Taiwan. 2. Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 3. Department of Nuclear Medicine, Taipei Medical University Hospital, Taipei, Taiwan. 4. Department of Medical Imaging and Radiological Technology, The Institute of Radiological Sciences, Tzu Chi University of Science and Technology, Hualien City, Taiwan. 5. Department of Biomedical Engineering and Environmental Sciences, National Tsinghua University, Hsinchu, Taiwan. 6. Department of Nuclear Medicine, Cheng Hsin General Hospital, Taipei, Taiwan. 7. Department of Nuclear Medicine, Camillian Saint Mary's Hospital Luodong, Yilan, Taiwan. 8. Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan. 9. Brain Research Center, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong Street, Taipei, 112, Taiwan. 10. PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, 100, Taiwan. 11. Molecular Imaging Center, National Taiwan University, Taipei, Taiwan. 12. PET Center, Department of Nuclear Medicine, Tri-Service General Hospital, Taipei, Taiwan. 13. Brain Research Center, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong Street, Taipei, 112, Taiwan. skyeyeh@live.com.
Abstract
BACKGROUND: Expression of translocator protein (TSPO) on the outer mitochondrial membrane of activated microglia is strongly associated with neuroinflammation. The second-generation PET ligand [18F]FEPPA specifically binds TSPO to enable in vivo visualization and quantification of neuroinflammation. We optimized a fully automated radiosynthesis method and evaluated the utility of [18F]FEPPA, the second-generation PET ligand specifically binds TSPO, in a mouse model of systemic LPS challenge to detect TSPO-associated signals of central and peripheral inflammation. In vivo dynamic PET/MR imaging was performed in LPS-induced and control mice after [18F]FEPPA administration. The relationship between the [18F]FEPPA signal and the dose of LPS was assessed. The cytokine levels (i.e., TNF-α, Il-1β, Il-6) in LPS-induced mice were measured by RT-PCR. Standard uptake value (SUV), total volume of distribution (VT) and area under the curve (AUC) were determined based on the metabolite-uncorrected plasma input function. Western blotting and immunostaining were used to measure TSPO expression in the brain. RESULTS: The fully automated [18F]FEPPA radiosynthesis produced an uncorrected radiochemical yield of 30 ± 2% within 80 min, with a radiochemical purity greater than 99% and specific activity of 148.9‒216.8 GBq/µmol. Significant differences were observed in the brain after [18F]FEPPA administration: SUV, VT and AUC were 1.61 ± 0.1, 1.25 ± 0.12 and 1.58 ± 0.09-fold higher in LPS-injected mice than controls. TNF-α, Il-1β and Il-6 mRNA levels were also elevated in the brains of LPS-injected mice. Western blotting revealed TSPO (p < 0.05) and Iba-1 (p < 0.01) were upregulated in the brain after LPS administration. In LPS-injected mice, TSPO immunoactivity colocalized with Iba-1 in the cerebrum and TSPO was significantly overexpressed in the hippocampus and cerebellum. The peripheral organs (heart, lung) of LPS-injected mice had higher [18F]FEPPA signal-to-noise ratios than control mice. CONCLUSIONS: Based on the current data on ligand specificity and selectivity in central tissues using 7 T PET/MR imaging, we demonstrate that [18F]FEPPA accumulations significant increased in the specific brain regions of systemic LPS-induced neuroinflammation (5 mg/kg). Future investigations are needed to determine the sensitivity of [18F]FEPPA as a biomarker of neuroinflammation as well as the correlation between the PET signal intensity and the expression levels of TSPO.
BACKGROUND: Expression of translocator protein (TSPO) on the outer mitochondrial membrane of activated microglia is strongly associated with neuroinflammation. The second-generation PET ligand [18F]FEPPA specifically binds TSPO to enable in vivo visualization and quantification of neuroinflammation. We optimized a fully automated radiosynthesis method and evaluated the utility of [18F]FEPPA, the second-generation PET ligand specifically binds TSPO, in a mouse model of systemic LPS challenge to detect TSPO-associated signals of central and peripheral inflammation. In vivo dynamic PET/MR imaging was performed in LPS-induced and control mice after [18F]FEPPA administration. The relationship between the [18F]FEPPA signal and the dose of LPS was assessed. The cytokine levels (i.e., TNF-α, Il-1β, Il-6) in LPS-induced mice were measured by RT-PCR. Standard uptake value (SUV), total volume of distribution (VT) and area under the curve (AUC) were determined based on the metabolite-uncorrected plasma input function. Western blotting and immunostaining were used to measure TSPO expression in the brain. RESULTS: The fully automated [18F]FEPPA radiosynthesis produced an uncorrected radiochemical yield of 30 ± 2% within 80 min, with a radiochemical purity greater than 99% and specific activity of 148.9‒216.8 GBq/µmol. Significant differences were observed in the brain after [18F]FEPPA administration: SUV, VT and AUC were 1.61 ± 0.1, 1.25 ± 0.12 and 1.58 ± 0.09-fold higher in LPS-injected mice than controls. TNF-α, Il-1β and Il-6 mRNA levels were also elevated in the brains of LPS-injected mice. Western blotting revealed TSPO (p < 0.05) and Iba-1 (p < 0.01) were upregulated in the brain after LPS administration. In LPS-injected mice, TSPO immunoactivity colocalized with Iba-1 in the cerebrum and TSPO was significantly overexpressed in the hippocampus and cerebellum. The peripheral organs (heart, lung) of LPS-injected mice had higher [18F]FEPPA signal-to-noise ratios than control mice. CONCLUSIONS: Based on the current data on ligand specificity and selectivity in central tissues using 7 T PET/MR imaging, we demonstrate that [18F]FEPPA accumulations significant increased in the specific brain regions of systemic LPS-induced neuroinflammation (5 mg/kg). Future investigations are needed to determine the sensitivity of [18F]FEPPA as a biomarker of neuroinflammation as well as the correlation between the PET signal intensity and the expression levels of TSPO.
Authors: Pablo M Rusjan; Alan A Wilson; Peter M Bloomfield; Irina Vitcu; Jeffrey H Meyer; Sylvain Houle; Romina Mizrahi Journal: J Cereb Blood Flow Metab Date: 2011-04-27 Impact factor: 6.200
Authors: Paolo Zanotti-Fregonara; Mattia Veronese; Belen Pascual; Robert C Rostomily; Federico Turkheimer; Joseph C Masdeu Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-17 Impact factor: 9.236
Authors: J Versijpt; J C Debruyne; K J Van Laere; F De Vos; J Keppens; K Strijckmans; E Achten; G Slegers; R A Dierckx; J Korf; J L De Reuck Journal: Mult Scler Date: 2005-04 Impact factor: 6.312
Authors: Akihiro Takano; Fredrik Piehl; Jan Hillert; Andrea Varrone; Sangram Nag; Balázs Gulyás; Per Stenkrona; Victor L Villemagne; Christopher C Rowe; Richard Macdonell; Nabil Al Tawil; Thomas Kucinski; Torsten Zimmermann; Marcus Schultze-Mosgau; Andrea Thiele; Anja Hoffmann; Christer Halldin Journal: EJNMMI Res Date: 2013-04-24 Impact factor: 3.138
Authors: William A Banks; Alicia M Gray; Michelle A Erickson; Therese S Salameh; Mamatha Damodarasamy; Nader Sheibani; James S Meabon; Emily E Wing; Yoichi Morofuji; David G Cook; May J Reed Journal: J Neuroinflammation Date: 2015-11-25 Impact factor: 8.322
Authors: Alejandra Rios; Travis S Holloway; Philip H Chao; Christian De Caro; Chelsea C Okoro; R Michael van Dam Journal: Sci Rep Date: 2022-06-17 Impact factor: 4.996